{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:01:15Z","timestamp":1762898475875},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,4,9]],"date-time":"2009-04-09T00:00:00Z","timestamp":1239235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Syst"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10916-009-9284-7","type":"journal-article","created":{"date-parts":[[2009,4,8]],"date-time":"2009-04-08T06:25:33Z","timestamp":1239171933000},"page":"701-707","source":"Crossref","is-referenced-by-count":7,"title":["Benefits of Pharmacogenomics in Drug Development\u2014Earlier Launch of Drugs and Less Adverse Events"],"prefix":"10.1007","volume":"34","author":[{"given":"Wataru","family":"Ohashi","sequence":"first","affiliation":[]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,4,9]]},"reference":[{"key":"9284_CR1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"W. E. Evans","year":"2003","unstructured":"Evans, W. E., and Mcleod, H. L., Pharmacogenomics\u2014Drug disposition, drug targets and side effects. N. Engl. J. Med. 348:538\u2013549, 2003. doi: 10.1056\/NEJMra020526 .","journal-title":"N. Engl. J. Med"},{"key":"9284_CR2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","volume":"348","author":"R. Weinshilboum","year":"2003","unstructured":"Weinshilboum, R., Inheritance and drug response. N. Engl. J. Med. 348:529\u2013537, 2003. doi: 10.1056\/NEJMra020021 .","journal-title":"N. Engl. J. Med"},{"key":"9284_CR3","first-page":"192","volume":"41","author":"F. R. Ernst","year":"2001","unstructured":"Ernst, F. R., and Grizzle, A. J., Drug related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc. 41:192\u2013199, 2001.","journal-title":"J. Am. Pharm. Assoc"},{"key":"9284_CR4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z. Desta","year":"2002","unstructured":"Desta, Z., Zhao, X., Shin, J. G., et al., Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913\u2013958, 2002. doi: 10.2165\/00003088-200241120-00002 .","journal-title":"Clin. Pharmacokinet"},{"key":"9284_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10038-005-0354-5","volume":"51","author":"T. Mushiroda","year":"2006","unstructured":"Mushiroda, T., Ohnishi, Y., Saito, S., et al., Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51:249\u2013253, 2006. doi: 10.1007\/s10038-005-0354-5 .","journal-title":"J. Hum. Genet"},{"issue":"2","key":"9284_CR6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/107602960601200211","volume":"12","author":"W. Viroj","year":"2006","unstructured":"Viroj, W., Pharmacogenetic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin. Appl. Thromb. Hemost. 12 (2)219\u2013222, 2006. doi: 10.1177\/107602960601200211 .","journal-title":"Clin. Appl. Thromb. Hemost"},{"key":"9284_CR7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00008571-200008000-00003","volume":"10","author":"L. R. Cardon","year":"2000","unstructured":"Cardon, L. R., Idury, R. M., Harris, T. J., et al., Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenemics. 10:503\u2013510, 2000. doi: 10.1097\/00008571-200008000-00003 .","journal-title":"Pharmacogenemics"},{"key":"9284_CR8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/009286150103500134","volume":"35","author":"M. Fung","year":"2001","unstructured":"Fung, M., Thornton, A., Mybeck, K., et al., Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets\u20141960 to 1999. Drug Inf. J. 35:293\u2013317, 2001.","journal-title":"Drug Inf. J."},{"key":"9284_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pst.286","volume":"7","author":"S. Huges","year":"2008","unstructured":"Huges, S., Huges, A., Brothers, C., et al., PREDICT-1(CNA106030). The first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm. Stat. 7:121\u2013129, 2008. doi: 10.1002\/pst.286 .","journal-title":"Pharm. Stat"},{"issue":"4","key":"9284_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1248\/yakushi.128.575","volume":"128","author":"K. Sai","year":"2008","unstructured":"Sai, K., Sawada, J., Minami, H., et al., Irinotecan pharmacogenetics in Japanese cancer patients: Roles of UGTA1*6 and 28. Yakugaku. Zasshi. 128 (4)575\u2013584, 2008. doi: 10.1248\/yakushi.128.575 .","journal-title":"Yakugaku. Zasshi"},{"key":"9284_CR11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/cncr.22806","volume":"110","author":"L. P. Garrison Jr.","year":"2007","unstructured":"Garrison, L. P. Jr., Lubeck, D., Lalla, D., et al., Cost-effectiveness analysis of traszumab in the adjuvant setting for treatment of Her2-positive breast cancer. Cancer. 110:489\u2013498, 2007. doi: 10.1002\/cncr.22806 .","journal-title":"Cancer"},{"key":"9284_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11239-007-0104-y","volume":"25","author":"F. Brian","year":"2008","unstructured":"Brian, F., and Lawrence, J., Pharmacogenetics of warfarin; regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis. 25:45\u201351, 2008. doi: 10.1007\/s11239-007-0104-y .","journal-title":"J. Thromb. Thrombolysis"},{"key":"9284_CR13","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1002\/sim.1281","volume":"21","author":"D. L. DeMets","year":"2002","unstructured":"DeMets, D. L., Clinical trials in the new millennium. Stat. Med. 21:2779\u20132787, 2002. doi: 10.1002\/sim.1281 .","journal-title":"Stat. Med"},{"key":"9284_CR14","unstructured":"McWilliam, A., Lutter, R., Nardinelli, C. et al., Health Care Savings from personalizing Medicine Using Genetic testing. AEI Bookings Joint Center for Regulatory Studies, Working Paper 6-23, 2006."},{"key":"9284_CR15","unstructured":"Ministry of Education, Culture, Sports, Science and Technology, Leading Project. Biobank Japan. http:\/\/www.biobankjp.org\/info\/IC0802.pdf . 2005."},{"issue":"3","key":"9284_CR16","first-page":"1","volume":"29","author":"D. L. Veenstra","year":"2000","unstructured":"Veenstra, D. L., Higashi, M. K., and Phillips, K. A., Assessing the cost-effectiveness of pharmacogenomics. AAPS. PharmSci. 29 (3)1\u201311, 2000.","journal-title":"AAPS. PharmSci"},{"key":"9284_CR17","unstructured":"Japan Pharmaceutical Manufacturers Association, Questionnaire about pharmacogenomics. https:\/\/www1.meteo-intergate.com\/news\/letter\/119\/ , 2007"},{"issue":"13","key":"9284_CR18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M. Hurlen","year":"2002","unstructured":"Hurlen, M., Abdelnoor, M., Smith, P., et al., Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 347 (13)969\u2013974, 2002. doi: 10.1056\/NEJMoa020496 .","journal-title":"N. Engl. J. Med"},{"key":"9284_CR19","first-page":"19426","volume-title":"Clinical research and development","author":"C. Gallen","year":"2006","unstructured":"Gallen, C., Clinical research and development. Wyeth Pharmaceuticals, Collegeville, p. 19426, 2006."},{"key":"9284_CR20","unstructured":"Japan Pharmaceutical Manufacturers Association, Proposal for extension of patent period, February, 2009 http:\/\/www.jpo.go.jp\/shiryou\/toushin\/shingikai\/pdf\/entyou-wg03_shiryou\/entyou-wg_shiryou03.pdf ."},{"key":"9284_CR21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00103-003-0697-z","volume":"46","author":"R. R. Shah","year":"2003","unstructured":"Shah, R. R., Regulatory aspects of pharmacogenetics and pharmacogenomics. Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz. 46:855\u2013867, 2003. doi: 10.1007\/s00103-003-0697-z .","journal-title":"Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz"},{"key":"9284_CR22","unstructured":"Yatsuda Y., Sales rank of world medicines, Utobain News release, Jul 2007. http:\/\/www.utobrain.co.jp \/news-release\/2007\/070700\/NewsRelease0707.pdf"},{"key":"9284_CR23","unstructured":"The calculation is based on the data in \u201cCommission to facilitate marketing of effective and safe medicine\u201d, MHLW, October 30, 2006. http:\/\/www.mhlw.go.jp\/shingi\/2007\/07\/dl\/s0730-10a.pdf"},{"key":"9284_CR24","doi-asserted-by":"crossref","unstructured":"Saito, H., Current Status and Issues of Drug Development Strategy in Japan. Drug Deliv. Syst. 1, 65\u201372, 2002.","DOI":"10.2745\/dds.22.65"},{"key":"9284_CR25","unstructured":"Genelex. Pharmacogenetics: personalizing medicine today. In Health and DNA. Seattle, Washington U.S. 2007. http:\/\/www.healthanddna.com\/professional\/pharmacogenetics.html#2c9"},{"key":"9284_CR26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1086-5802(16)31229-3","volume":"41","author":"F. R. Ernst","year":"2001","unstructured":"Ernst, F. R., and Grizzle, A. J., Drug-related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc. 41:192\u2013199, 2001.","journal-title":"J. Am. Pharm. Assoc"},{"key":"9284_CR27","unstructured":"Bureau of Labor Statistics, Consumer price index for medical care, 2002\u20132006."},{"issue":"22","key":"9284_CR28","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","volume":"352","author":"M. J. Rieder","year":"2005","unstructured":"Rieder, M. J., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352 (22)2285\u20132293, 2005. doi: 10.1056\/NEJMoa044503 .","journal-title":"N. Engl. J. Med"},{"key":"9284_CR29","unstructured":"Genetic Information Nondiscrimination Act:GINA. http:\/\/www.house.gov\/apps\/list\/speech\/edlabor_dem\/rel050108.html"},{"key":"9284_CR30","unstructured":"SNP Genotyping and Analysis Markets. Kalorama Information, 2008. http:\/\/www.infoshop-japan.com\/publisher\/KL.shtml"},{"key":"9284_CR31","unstructured":"Cabinet Office, Government of Japan, Act on the Protection of Personal Information, May, 2003, http:\/\/www5.cao.go.jp\/seikatsu\/kojin\/houritsu\/index.html"},{"key":"9284_CR32","unstructured":"Ministry of Health, Labour and Welfare, Ethical Guidelines for Human Genome and Genetic Sequencing Research, December, 2004, http:\/\/www5.cao.go.jp\/seikatsu\/shingikai\/kojin\/20050127kojin-sanko2-3.pdf"}],"container-title":["Journal of Medical Systems"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10916-009-9284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10916-009-9284-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10916-009-9284-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T04:51:32Z","timestamp":1559451092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10916-009-9284-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,9]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["9284"],"URL":"https:\/\/doi.org\/10.1007\/s10916-009-9284-7","relation":{},"ISSN":["0148-5598","1573-689X"],"issn-type":[{"value":"0148-5598","type":"print"},{"value":"1573-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,9]]}}}